Vitamin and antioxidant rich diet increases MLH1 promoter DNA methylation in DMT2 subjects

Clinical Epigenetics

Table 3 MGMT group-specific methylation levels for each CpG and the mean methylation over the ten CpGs

Health group		CpG 1	CpG 2	CpG 3	CpG 4	CpG 5	CpG 6	CpG 7	CpG 8	CpG 9	CpG 10	Mean
NIDDM2		0,224	0,565	0,272	0,232	0,413	0,436	0,106	0,373*	0,103	0,853	0,420
	SE	0,163	0,270	0,127	0,165	0,191	0,173	0,139	0,155	0,142	0,426	0,192
	P	0,210	0,075	0,070	0,202	0,067	0,039	0,468	0,047	0,492	0,086	0,065
IFG		0,226	0,386	0,086	0,183	0,493	0,422	0,129	−1,599	0,168	0,856	0,204
	SE	0,143	0,310	0,088	0,125	0,224	0,214	0,158	1,840	0,255	0,310	0,146
	P	0,188	0,281	0,384	0,218	0,092	0,120	0,461	0,434	0,546	0,051	0,233
pooled		0,225	0,496*	0,200*	0,213	0,443*	0,431*	0,115	−0,386	0,128	0,854*	0,337*
	SE	0,110	0,198	0,087	0,109	0,140	0,129	0,101	0,721	0,125	0,279	0,130
	P	0,063	0,027	0,039	0,073	0,008	0,006	0,275	0,602	0,327	0,010	0,023

Paired t-test of methylation changes between baseline (T0) and 8 weeks (T1). CpG numbers 2, 3, 5, 6, and 10 and the mean methylation were significantly higher methylated in the intervention groups (pooled). Asterisks indicate significances at P < 0.05. NIDDM2, patients with non-insulin-dependent diabetes mellitus type 2; IFG, patients with impaired fasting glucose; LC, lean control group; SE, standard error of the mean.

ISSN: 1868-7083